In addition, the pan-cancer analysis and our result showed that the expression of SIGLEC15 may play distinctive roles in different human cancers, such as acting as an immunosuppressor in “hot tumor” non-small cell lung cancer, so anti-SIGLEC15 therapy was suitable for such tumor. This evidence concerns the gene SIGLEC15 and non-small cell lung carcinoma.